Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Neophore Limited currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's current patent activities are being reviewed by 2 distinct art units within the patent office, potentially reflecting a range of technical applications within the biotechnology sector.
The busiest examiner for the portfolio is NOLAN, JASON MICHAEL, who is currently handling 1 busiest examiner pending office action. The 1 busiest examiner pending office action is part of the 2 pending office actions currently on record. With 2 distinct examiners involved, practitioners must adapt their prosecution strategies to the specific guidelines of each individual. The presence of 2 distinct examiners means that the company's outcomes are not dependent on this individual's interpretation of the prior art.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| SHI, GENBIN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712285 | INDOLINES AS PROTAC COMPOUNDS | SHI, GENBIN | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18712311 | ISOINDOLINES AS PMS2 INHIBITORS | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | May 22, 2024 |
| 18712285 | INDOLINES AS PROTAC COMPOUNDS | SHI, GENBIN | 1628 | §103§112 | Non-Final OA | — | Pending | May 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeophore Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jason Michael Nolan has the most, with 1 of Neophore Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
